Simpler Grants.gov #PAR-25-248

NIH Funding for Cancer Research Using PLCO Biospecimens

This opportunity invites research organizations to apply for funding from the National Institutes of Health (NIH) to advance cancer etiology and early detection biomarker research using biospecimens from the NCI-sponsored PLCO Screening Trial Biorepository. - Government Buyer: - National Institutes of Health (NIH) - Products/Services Requested: - Research services focused on cancer etiology and early detection biomarkers - Mandatory use of PLCO Biorepository biospecimens, including: - Serial pre-diagnostic blood samples (screened arm participants) - One-time buccal cell collection (control arm participants) - Associated demographic, diet, lifestyle, smoking, screening, and clinical data - Unique/Notable Requirements: - Only projects utilizing PLCO biospecimens are eligible - Research may include biochemical and genetic analyses of cancer risk, biomarker discovery, and validation - Broad eligibility: nonprofits, government, educational institutions, businesses, and minority-serving organizations - No specific OEMs or commercial vendors are mentioned, as this is a grant for research services, not product procurement

Description

This Funding Opportunity Announcement (FOA) from the National Institutes of Health encourages applications to advance research in cancer etiology and early detection biomarkers using the unique biorepository resources of the NCI-sponsored PLCO Screening Trial. The PLCO Biorepository provides high-quality, prospectively collected, serial pre-diagnostic blood samples and buccal cells, along with associated demographic, lifestyle, and clinical data. The FOA supports a wide range of cancer research including biochemical and genetic analyses of cancer risk and discovery and validation of early detection biomarkers. Research projects must involve the use of PLCO biospecimens to be supported under this FOA.

View original listing